Methodology to Incorporate the BED and EUD in PatientSpecific 3-Dimensional Dosimetry for Non-Hodgkin's Lymphoma Patients Targeted with 131I Tositumomab Therapy

被引：0
|
作者：
Amro, H.
Wilderman, S.
Dewaraja, Y.
Roberson, P.
机构：
来源：
MEDICAL PHYSICS | 2009年 / 36卷 / 06期
关键词：
D O I：
10.1118/1.3181937
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
SU-FF-T455
引用
收藏
页数：2
相关论文
共 50 条
  • [11] 131I-Tositumomab (Bexxar®) Therapy of Refractory/Relapsed Non-Hodgkin Lymphoma: Clinical Experience
    Iagaru, A.
    Knox, S.
    Goris, M. L.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2008, 35 : S148 - S149
  • [12] Efficacy and safety of Bexxar® (tositumomab and iodine I 131 tositumomab) in obese patients with low-grade non-Hodgkin's lymphoma.
    Wahl, R
    Goldsmith, SJ
    Zasadny, KR
    Alavi, A
    Divgi, C
    Hankins, J
    JOURNAL OF NUCLEAR MEDICINE, 2003, 44 (05) : 415P - 415P
  • [13] I-131 Tositumomab myeloablative radioimmunotherapy for non-Hodgkin's lymphoma: Radiation dose to the testes
    Hattori, Naoya
    Gopal, Ajay
    Fisher, Darrell
    Durack, Lawrence
    Shields, Andrew
    Press, Oliver
    Rajendran, Joseph
    JOURNAL OF NUCLEAR MEDICINE, 2009, 50
  • [14] Essential Role of Nuclear Medicine Technology in Tositumomab and I-131-Tositumomab Therapeutic Regimen for Non-Hodgkin's Lymphoma
    Cole, William C.
    Barrickman, Jennifer
    Bloodworth, Glen
    JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY, 2006, 34 (02) : 67 - 73
  • [15] 131I-tositumomab myeloablative radioimmunotherapy for non-Hodgkin's lymphoma: radiation dose to the testes
    Hattori, Naoya
    Gopal, Ajay K.
    Shields, Andrew T.
    Fisher, Darrell R.
    Gooley, Ted
    Pagel, John M.
    Press, Oliver W.
    Rajendran, Joseph G.
    NUCLEAR MEDICINE COMMUNICATIONS, 2012, 33 (12) : 1225 - 1231
  • [16] Feasibility and safety of outpatient Bexxar® therapy (tositumomab and iodine I 131 tositumomab) for non-Hodgkin's lymphoma based on radiation doses to family members
    Rutar, FJ
    Augustine, SC
    Kaminski, MS
    Wahl, RL
    Siegel, JA
    Colcher, D
    CLINICAL LYMPHOMA, 2001, 2 (03): : 164 - 172
  • [17] Bexxar - Tositumomab and iodine I 131 tositumoma - Glaxosmithkline/Corixa - New treatment for non-Hodgkin's lymphoma
    不详
    FORMULARY, 2003, 38 (08) : 455 - 456
  • [18] Bexxar® (tositumomab and iodine I 131 tositumomab) is well tolerated and efficacious in heavily pretreated patients with non-Hodgkin's lymphoma (NHL) and mild thrombocytopenia.
    Goldsmith, SJ
    Kostakoglu, L
    Wahl, R
    Alavi, A
    Divgi, C
    Hankins, J
    Zelenetz, A
    Kaminski, M
    JOURNAL OF NUCLEAR MEDICINE, 2003, 44 (05) : 33P - 34P
  • [19] Bexxar, iodine I 131 tositumomab, effective in long term follow-up of non-Hodgkin's lymphoma
    Kaminski, Mark
    CANCER BIOLOGY & THERAPY, 2007, 6 (07) : 996 - 997
  • [20] Iodine I 131 tositumomab for patients with follicular non-Hodgkin's lymphoma (NHL): Overall clinical trial experience by histology.
    Vose, JM
    Zelenetz, AD
    Rohatiner, A
    Knox, S
    Stagg, R
    Kroll, S
    Tidmarsh, G
    Kaminski, MS
    BLOOD, 1999, 94 (10) : 89A - 89A
12345